

Corp. Off.: 502, Kanakia Atrium - 2,
Next to Courtyard Marriott Hotel,
Andheri Kurla Road, Andheri (East),
Mumbai - 400 093 (India)
Ph.: +9122 61933100 Fax : +91 22 61933114

12th November, 2020

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Kind Attn: General Manager-DCS

Scrip Code: 533543

Kind Attn: Head- Listing

Symbol: BROOKS

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 2nd quarter and half yearly ended 30th September, 2020. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow Statement as at 30.09.2020 together with the Limited Review Report are attached.


This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**


(Jyoti Sancheti)



Company Secretary cum Compliance Officer

Membership No. F9639

Encl.: As Stated Above

Statements of Unaudited Financial Results for the Quarter/ Half year ended 30th September, 2020

(Rs. In Lakhs)

Particulars	Standalone						Consolidated	
	Quarter Ended			Half Year Ended		Year Ended	Quarter Ended	Half Year Ended
	30-Sep-20	30-Jun-20	30-Sep-19	30-Sep-20	30-Sep-19	31-Mar-20	30-Sep-20	30-Sep-20
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited
1 Income								
Revenue from operations	2,924.41	1,246.57	1,414.70	4,170.98	3,096.88	6,968.85	2,924.41	2,924.41
Other Income	52.30	11.17	7.28	63.47	14.16	40.63	52.30	52.30
Total income	2,976.71	1,257.74	1,421.98	4,234.45	3,111.04	7,009.48	2,976.71	2,976.71
2 Expenses								
(a) Cost of materials consumed	1,495.63	1,003.60	1,083.45	2,499.23	2,110.37	4,949.80	1,495.63	1,495.63
(b) Purchase of Stock in Trade	240.89	10.90	-	251.79	-	61.48	240.89	240.89
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(55.80)	(253.68)	(104.83)	(309.48)	(26.83)	(328.90)	(55.80)	(55.80)
(d) Employees benefits expenses	362.68	307.00	338.16	669.68	656.36	1,338.41	362.68	362.68
(e) Finance Costs	80.28	77.64	79.72	157.92	162.55	335.03	80.28	80.28
(f) Depreciation and amortization expenses	170.83	197.58	160.14	368.41	317.35	664.76	170.83	170.83
(g) Other expenses	345.65	203.41	291.06	549.06	562.68	1,340.27	345.65	345.65
Total Expenses	2,640.16	1,546.45	1,847.70	4,186.61	3,782.48	8,360.85	2,640.16	2,640.16
3 Profit/(Loss) before exceptional item and tax	336.55	(288.71)	(425.72)	47.84	(671.44)	(1,351.37)	336.55	336.55
4 Exceptional items	-	-	-	-	-	-	-	-
5 Profit/(Loss) from ordinary activities before tax	336.55	(288.71)	(425.72)	47.84	(671.44)	(1,351.37)	336.55	336.55
6 Tax Expense:								
Deferred Tax Liability / (Assets)	-	-	(238.02)	-	(110.32)	174.37	-	-
MAT credit reversal	-	-	-	-	-	911.85	-	-
7 Net Profit/(loss) after tax	336.55	(288.71)	(187.70)	47.84	(561.12)	(2,437.60)	336.55	336.55
8 Other Comprehensive Income								
Items That will not be reclassified into Profit or loss								
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	(2.96)	(2.46)	2.69	(5.42)	0.23	14.73	(2.96)	(2.96)
9 Total Comprehensive Income for the period	333.59	(291.17)	(185.02)	42.42	(560.89)	(2,422.87)	333.59	333.59
Net Profit attributable to								
Owners of equity	-	-	-	-	-	-	336.55	336.55
Non Controlling Interest	-	-	-	-	-	-	-	-
Total Comprehensive Income attributable to								
Owners of Equity	-	-	-	-	-	-	333.59	333.59
Non Controlling Interest	-	-	-	-	-	-	-	-
10 Paid-up equity share capital (Face Value of Rs. 10 each)	2,470.28	2,470.28	1,703.64	2,470.28	1,703.64	2,470.28	2,470.28	2,470.28
11 Other Equity	7,371.32	7,371.32	8,340.95	7,371.32	8,340.95	7,371.32	-	-
12 Earnings per share (of Rs. 10/- each)								
(not annualised)								
(a) Basic	1.35	(1.17)	(1.12)	0.19	(3.34)	(13.84)	1.35	1.35
(b) Diluted	1.35	(1.17)	(1.12)	0.19	(3.34)	(13.84)	1.35	1.35

For Brooks Laboratories Ltd.

 **Chairman**

Notes:

- 1 The above IND AS Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on 12th November, 2020 and have undergone 'Limited Review' by the Statutory Auditors of the company.
- 2 The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July,
- 3 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- 4 During the quarter ended, the company has invested into a company "Brooks Steriscience Limited" through equity shares of 50,000 at the price of Rs. 10 per share amounting to Rs. 5,00,000. Further it has also invested into another company "Steribrooks Penoms Private Limited" through equity shares of 7,963 at the price of Rs. 10 per share amounting to Rs. 79,630 (out of total Equity Capital of Rs. 1,79,630). These respective investments are classified as Subsidiary & Associate in the books of the Company.
- 5 The Company has invested in Subsidiary and Associate during the quarter, hence the comparative figures of previous year and quarter / half year ended are not available for consolidation.
- 6 The Company operates in one reportable business segment i.e. "Pharmaceuticals".
- 7 Figures of the previous reporting period has been reclassified/ regrouped wherever necessary to correspond with the figures of the current reporting period.

Place : Mumbai
Date : 12th November, 2020

For and Behalf of the Board

Atul Ranchal
Din : 01998361
Wholetime Director



Statement of Assets & Liabilities as at 30th September, 2020

(Rs. in Lakhs)

	Particulars	Standalone		Consolidated
		As at September 30, 2020 (Unaudited)	As at March 31, 2020 (Audited)	As at September 30, 2020 (Unaudited)
A	ASSETS			
1	Non Current Assets			
	(a) Property, Plant and Equipment	10,878.70	11,217.70	10,878.70
	(b) Right to use Assets	55.56	67.48	55.56
	(c) Intangible asset	61.54	17.04	61.54
	(d) Intangible asset under Development	10.99	10.99	10.99
	(e) Investment Property	-	-	-
	(f) Financial Assets			
	(i) Investments	7.80	2.00	2.80
	(ii) Other Financial Assets	160.87	162.73	160.87
	(g) Income Tax Assets (Net)	496.92	496.55	496.92
	(h) Deferred Tax Assets (Net)	-	-	-
	(i) Other Non Current Assets	19.73	20.11	19.73
	Total Non - Current Assets	11,692.11	11,994.60	11,687.11
2	Current assets			
	(a) Inventories	2,961.05	1,377.49	2,961.05
	(b) Financial Assets			
	(i) Trade receivables	1,739.30	1,556.20	1,739.30
	(ii) Cash and Cash Equivalents	21.91	39.60	21.91
	(iii) Bank Balances other than Cash & cash equivalents	115.38	113.18	115.38
	(iv) Other Financial Assets	170.74	60.19	170.74
	(c) Other Current Assets	840.35	645.13	840.35
	Total Current Assets	5,848.73	3,791.79	5,848.73
	TOTAL ASSETS	17,540.84	15,786.39	17,535.84
B	EQUITY AND LIABILITIES			
1	Equity			
	(a) Equity Share Capital	2,470.28	2,470.28	2,470.28
	(b) Other Equity	7,413.75	7,371.32	7,413.75
	Equity attributable to Owners of the Company	9,884.03	9,841.60	9,884.03
	Non-Controlling interests	-	-	-
	Total Equity	9,884.03	9,841.60	9,884.03
2	Liabilities			
	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	1,106.84	1,139.93	1,106.84
	(ii) Lease Liability	39.34	52.91	39.34
	(b) Provisions	206.98	172.04	206.98
	Total Non - Current Liabilities	1,353.16	1,364.88	1,353.16
3	Current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	1,430.65	1,261.03	1,430.65
	(ii) Lease liability	25.63	23.12	25.63
	(iii) Trade Payables			
	- Due to micro and small enterprises	451.14	445.56	451.14
	- Due to Others	2,693.62	2,161.05	2,693.62
	(iii) Other Financial Liabilities	582.28	489.02	582.28
	(b) Other current liabilities	1,061.62	144.12	1,056.62
	(c) Provisions	58.69	56.02	58.69
	Total Current Liabilities	6,303.65	4,579.91	6,298.65
	TOTAL EQUITY AND LIABILITIES	17,540.84	15,786.39	17,535.84

Note : For comparative figures of previous period, refer Note no. 5 in the Statements of Unaudited Financial Results

For Brooks Laboratories Limited

Place : Mumbai
 Date : 12th November, 2020

Atul Ranchar
 Din : 01998361
 Wholtime Director



BROOKS LABORATORIES LIMITED
Cash Flow Statement for the period ended 30 September, 2020

(Rs. In Lakhs)

Particulars	Standalone		Consolidated
	Period ended	Period ended	Period ended
	30 September 2020	30 September 2019	30 September 2020
	Unaudited	Unaudited	Unaudited
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net (loss) / profit before tax	47.85	(671.43)	47.85
Adjustments for			
Depreciation and amortisation expense	368.41	317.35	368.41
Finance cost	157.92	162.55	157.92
Interest income	(11.26)	(5.80)	(11.26)
Remeasurement of Defined benefit obligations	(5.42)	0.32	(5.42)
Dividend from current investments	(0.28)	(0.35)	(0.28)
Profit on sale of asset	-	-	-
Loss on discarded asset	-	-	-
Provision for Expected credit loss	(3.47)	28.73	(3.47)
Unrealised Foreign Exchange Gain	(11.06)	-	(11.06)
Operating profit before working capital changes	542.71	(168.64)	542.71
Adjustments for changes in working capital:			
Decrease / (increase) in Trade Receivables	(165.75)	(486.45)	(165.75)
Decrease / (increase) in Inventories	(1,583.56)	(2.70)	(1,583.56)
Decrease / (increase) in Other Assets	(194.84)	(34.45)	(194.84)
Decrease / (increase) in Other Financial Assets	(110.10)	(1.71)	(110.10)
(Decrease) / Increase in Trade and Other Payables	538.15	658.95	538.15
(Decrease) / Increase in Other Financial Liabilities	81.23	22.99	76.23
(Decrease) / Increase in Other Liabilities	917.50	41.04	917.50
(Decrease) / Increase in Long term Provisions	34.94	23.20	34.94
(Decrease) / Increase in Short term Provisions	2.68	2.09	2.68
Cash generated from / (used in) operations	62.97	54.33	57.97
Direct taxes paid (net of refunds received)	(0.37)	(0.34)	(0.37)
Net cash (used in) / from generated from operating activities	62.60	54.00	57.61
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment (including capital work in progress and capital	(61.98)	(226.94)	(61.98)
Investment in Associate company	(0.80)	-	(0.80)
Investment in Subsidiary	(5.00)	-	-
Net (investments in) / proceeds from bank deposits (having original maturity of more than three	(2.21)	(13.14)	(2.21)
Interest received	9.84	5.09	9.84
Dividend received	0.28	0.35	0.28
Net cash (used in) / generated from investing activities	(59.87)	(234.64)	(54.87)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Money received against share warrants and issue of shares on Rights basis	-	256.26	-
Proceeds / (Repayment) from borrowings (net)	152.54	(45.75)	152.54
Repayment of Lease Liabilities	(11.06)	-	(11.06)
Finance costs paid	(161.89)	(171.58)	(161.89)
Net cash (used in) / from financing activities	(20.41)	38.93	(20.40)
Net decrease in cash and cash equivalents (A+B+C)	(17.68)	(141.71)	(17.67)
Cash and cash equivalents at the beginning of the year	39.59	249.85	39.59
Cash and cash equivalents at the end of the year	21.91	108.14	21.91

Note: For comparative figures of previous period, refer Note no. 5 in the Statements of Unaudited Financial Results

Place : Mumbai
Date : 12th November, 2020

For and on Behalf of Board

Atul Ranchal
Din : 01998361
Wholtime Director



SGCO & Co. LLP

Chartered Accountants

Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter and half year ended September 30, 2020 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,
The Board of Directors
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter and half year ended September 30, 2020. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S G C O & Co. LLP

Chartered Accountants

Firm's Registration No. 112081W/W100184


Suresh Murarka

Partner

Mem.No. 044739

UDIN : 20044739AAAA104701



Place : Mumbai

Date : 12th November, 2020

4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. info@sgco.co.in
www.sgco.co.in

SGCO & Co.LLP

Chartered Accountants

Independent Auditor's Review Report on Consolidated Unaudited Financial Results of Brooks Laboratories Limited for the quarter and half year ended September 30, 2020 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,
The Board of Directors
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Brooks Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2020 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

- a) Subsidiary:
Brooks Steriscience Limited
- b) Associate:
Steribrooks Penems Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the unaudited financial statements referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and

4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai – 400 069

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail. info@sgco.co.in
www.sgco.co.in



SGCO & Co. LLP
Chartered Accountants

measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of

Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial statements / financial information / financial results of one subsidiary (Brooks Steriscience Limited) included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total assets of Rs. 5.00 lakhs as at September 30, 2020 and total revenues of Rs. Nil, total net profit/(loss) after tax of Rs. Nil and total comprehensive income / loss of Rs. Nil, for the quarter and half year ended September 30, 2020 respectively, and cash flows (net) of Rs. 5.00 lakhs for the half year ended September 30, 2020, as considered in the consolidated unaudited financial results. The consolidated financial statements include the Group's share of net profit of Rs. Nil for the quarter and half year ended September 30, 2020, as considered in the consolidated unaudited financial statements, in respect of one associate (Steribrooks Penems Private Limited) whose financial statement/ financial information/ financial results are unaudited and have been furnished to us by the Management. These interim financial statements / financial information / financial results are unaudited and have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited financial statements furnished to us by the Management and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For S G C O & Co. LLP

Chartered Accountants

Firm's Registration No. 112081W/W100184


Suresh Murarka

Partner

Mem.No. 044739

UDIN : 20044739 AAAA IQ 8384



Place : Mumbai

Date : 12th November, 2020